A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf079 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Patrick Y Wen und 54 weiteren Autor:innen. Beteiligte Einrichtung: Adult Brain Tumor Consortium, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Immunotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
For newly diagnosed glioblastoma (GBM), a combination of upfront surgical immunotherapy with aglatimagene besadenovec (CAN-2409), followed by chemoradiation and then adjuvant nivolumab has not been tested. The aim of this study was to test the safety of this regimen and determine metrics of immune activation that may correlate with clinical outcomes.
Methods
Forty-one patients with suspected newly diagnosed GBM by imaging were enrolled in this multi-institutional, open-label, phase 1b clinical trial before surgical resection. Frozen section confirmation of high-grade glioma was required for administration of CAN-2409. This was then followed with chemoradiation and adjuvant nivolumab. Tumor and blood were assayed for genetic and immune markers before and during treatment.
Results
The regimen was well tolerated and generated measurable immune activation. Factors linked to survival were identified, such as baseline mutated gene pairs (eg, MED15/HRC), tumor immune cell composition, and changes in systemic cytokine, immune cells, and T-cell diversity. The most significant serial systemic immune changes were observed in a long-term survivor subset of patients with gross total resection (GTR)/methylated methylguanine methyltransferase (MGMT) promoter tumors. Median overall survival (mOS) in these patients was 30.6 months, while it was less for patients with unmethylated or subtotal resections.
Conclusions
These findings suggest the opportunity for patient stratification and the potential for more durable antitumor immune responses in future clinical trials of this multimodal standard of care and combined immunotherapy regimen. ClinicalTrials.gov identifier: NCT03576612.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Adult Brain Tumor Consortium, Baltimore, Maryland, USA.
- Center for Neuro-oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Candel Therapeutics, Needham, Massachusetts, USA.
- Stanford University, Stanford, California, USA.
- Mount Sinai, New York, New York, USA.
- Department of Neurosurgery, Division of Neuro-oncology, Johns Hopkins University Medical Center, Baltimore, Maryland, USA.
ORCID-Profile: Stuart A Grossman, Tobias Walbert, Stephen J Bagley, E Antonio Chiocca
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Wen, P. Y., Manzanera, A., Duault, C., Gonzalez-Kozlova, E., Lopez, L., Grossman, S. A., Ye, X., Fisher, J., Lee, I., Walbert, T., Snyder, J., Brem, S., Desai, A., Bagley, S. J., Kakani, C., Strowd, R., Tatter, S., Laxton, A., Lesser, G., …, & Chiocca, E. A. (2025). A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf079
Vancouver
Wen PY, Manzanera A, Duault C, Gonzalez-Kozlova E, Lopez L, Grossman SA, et al. A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf079
BibTeX
@article{Wen2025,
author = {Wen, Patrick Y and Manzanera, Andrea and Duault, Caroline and Gonzalez-Kozlova, Edgar and Lopez, Lenika and Grossman, Stuart A and Ye, Xiaobu and Fisher, Joy and Lee, Ian and Walbert, Tobias and Snyder, James and Brem, Steven and Desai, Arati and Bagley, Stephen J and Kakani, Chandana and Strowd, Roy and Tatter, Stephen and Laxton, Adrian and Lesser, Glenn and Amankulor, Nduka and Lieberman, Frank and Drappatz, Jan and Mantica, Megan and Triggs, Dan and Haymaker, Cara and Wistuba, Ignacio I and Al-Atrash, Gheath and Mendoza Perez, Julia and Futreal, Andrew and Little, Latasha D and Islam, M D Habibul and Duose, Dzifa and Jiang, Peixin and Reuben, Alexandre and Lawler, Sean E and Pichavant, Mina and Gentles, Andrew and Bendall, Sean and Kong, Alex and Camacho, Christine and Del Valle, Diane and Kim-Schulze, Seunghee and Gnjatic, Sacha and Sharon, Elad and Nowicki, M Oskar and Peruzzi, Pierpaolo and Lane, Doug and Aguilar-Cordova, Estuardo and Aguilar, Laura K and Nichols, Garrett and Dwyer, Jessica and Tak, Paul Peter and Maecker, Holden and Barone, Francesca and Chiocca, E Antonio},
title = {A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf079}
}
EUVIMED